News

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...
What’s powering a $26.28 billion opportunity?The global ophthalmology drugs market, valued at US$18.34 billion in 2024 stood ...
Boehringer Ingelheim has raised hopes of a more patient-friendly option with the start of phase 2 testing of BI 1815368, ...
EMERYVILLE, CA, USA I July 02, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...